The Quantellect read.As of Nov 19, 2026, 3 active firms cover Aurinia Pharmaceuticals Inc: 1 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets are tightly clustered, $16.00 to $18.00, so the covering firms are broadly aligned. The average target of $16.67 sits 10% above the current $15.13. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 15% this year and 18% next, consensus EPS building from about $0.19 next quarter toward $1.16 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Neutral
Strong Buy00%
Buy133%
Neutral267%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$16.67
+10.1% upside
Average target across 3 active firms as of Nov 19, 2026 vs $15.14 current
Highest Target$18.00
Average Target$16.67
Lowest Target$16.00
Detailed analyst forecasts for AUPH
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 1 of 3 active firms rate AUPH a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
AUPH EPS & revenue forecast
EPS · NEXT QUARTER
$0.19
Range $0.17 – $0.21 · 2 analysts · -24% YoY
Next period, 2 analysts expect Aurinia Pharmaceuticals Inc to earn $0.19 a share (range $0.17 – $0.21), versus $0.25 a year earlier. Full-year consensus is $0.97, growing to $1.16 the year after.
REVENUE · NEXT QUARTER
$83.0M
Range $80.9M – $85.0M · 2 analysts · +12% YoY
Revenue is expected to reach $83.0M (range $80.9M – $85.0M), +12.0% year-over-year. Full-year consensus is $330.1M, rising to $385.7M next year.
Top analysts covering Aurinia Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AUPH.
#1
Arthur He
HC Wainwright & Co. · Rank #198
Buy
$17.00+12.3% to target
Overall win rate
50%
+ Follow
#2
Joseph Schwartz
Leerink Partners · Rank #242
Neutral
$16.00+5.7% to target
Overall win rate
36%
+ Follow
#3
DM
Douglas Miehm
RBC Capital · Rank #263
Neutral
$16.00+5.7% to target
Overall win rate
43%
+ Follow
#4
MR
Maury Raycroft
Jefferies
Buy
$21.00+38.8% to target
Coverage
—
+ Follow
#5
SK
Stacy Ku
TD Cowen
Buy
$18.00+18.9% to target
Coverage
—
+ Follow
AUPH stock forecast FAQ
What is AUPH's average 12-month price target?+
The 3 active firms with a live target average $16.67 for Aurinia Pharmaceuticals Inc over the next 12 months, ranging from a $18.00 high to a $16.00 low, as of Nov 19, 2026.
Is AUPH stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 3 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for AUPH?+
The Street-high target is $18.00 (TD Cowen), and the Street-low is $16.00 (RBC Capital). The average of all 3 active-firm targets is $16.67.
How many active Wall Street firms cover AUPH?+
3 active firms have a recognized rating on Aurinia Pharmaceuticals Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering AUPH?+
Among analysts who currently cover AUPH, Arthur He of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #198). Their current call is Buy with a $17.00 target.
What is Aurinia Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.19 per share (range $0.17 – $0.21) across 2 analysts. Full-year EPS is projected at $0.97, rising to $1.16 the following year.
How much revenue is Aurinia Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $83.0M (range $80.9M – $85.0M). Full-year revenue is projected at $330.1M, growing to $385.7M next year.
Have analysts been upgrading or downgrading AUPH lately?+
As of Nov 19, 2026, 1 of 3 active firms rate AUPH a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AUPH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.